TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Feb 21, 2023 14:02 JST
Source:
Eisai
Dissolution of Bracco-Eisai Joint Venture
TOKYO, Feb 21, 2023 - (JCN Newswire) - Bracco Imaging S.p.A. and Eisai Co., Ltd. announced today that the joint venture regarding the company Bracco-Eisai Co., Ltd. (Ratio of Shares Held: Bracco 51% Eisai 49%), will be dissolved as of March 31, 2023. As a result, Bracco will acquire all shares of Bracco-Eisai held by Eisai and change its name from Bracco-Eisai to Bracco Japan, Co., Ltd. as of April 1, 2023.
Bracco and Eisai established Bracco-Eisai in 1990 with the aim of establishing a contrast agent business in Japan. The companies launched the non-ionic contrast agent Iomeron and the macrocyclic non-ionic contrast agent ProHance for MRI in 1994, and have worked together in a friendly partnership for more than 30 years. After comprehensive consideration, the companies decided to dissolve the joint venture in order to respond quickly and flexibly to the changing environment surrounding the healthcare industry and achieve sustainable contributions to patients through these products.
Regarding Iomeron and ProHance, products that Eisai and Bracco-Eisai have co-promoted thus far, Eisai and Bracco-Japan will continue to co-promote these products between April 1, 2023 and March 31, 2024, with Bracco-Japan as the domestic manufacturer and Eisai as the distributor. Bracco Japan will exclusively commercialize the products from April 1, 2024.
"The Asia-Pacific region plays a leading role in diagnostic imaging and is expected to grow faster than other global markets," said Fulvio Renoldi Bracco, Vice-Chairman & CEO of Bracco Imaging S.p.A. "Bracco has had a considerable presence in Japan for many years and will continue to strengthen its relationships with customers in order to better understand and meet the needs of customers in Japan. We will continue to provide better diagnostic imaging technology and services."
"We are deeply grateful to Bracco, with whom we have worked together for more than 30 years since Bracco-Eisai's founding to contribute to patients in the field of diagnostic imaging." said Haruo Naito, Chief Executive Officer at Eisai Co., Ltd. "Based on our human health care concept, Eisai will continue to play a role in providing information on both Iomeron and ProHance until the end of March 2024, and will take all possible measures to ensure a smooth transfer of operations, so that Bracco Japan can maintain its contribution to patients."
Media Inquiries:
Bracco Imaging S.p.A.
Bracco Imaging Media Relations
TEL: +39-340-9016191
Bracco Eisai Co.,Ltd
Public Relations
TEL: +81-(0)3-5319-3381
Eisai Co., Ltd.
Public Relations Department
TEL: +81-(0)3-3817-5120
Source: Eisai
Sectors: Healthcare & Pharm
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
February 10 2026 12:34 JST
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
February 06 2026 10:31 JST
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
January 26 2026 10:37 JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
January 21 2026 15:44 JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
More Press release >>
Latest Press Release
International Women's Day: Why Menopause May Be a Missed Cardiovascular Risk Window
Mar 06, 2026 20:00 JST
TANAKA Develops World's First High-Performance Palladium Hydrogen Permeable Membrane Exhibiting High Hydrogen Purification Performance at Temperatures around 100 degrees C
Mar 05, 2026 22:00 JST
Honda to Begin Sales of Two U.S.-built Vehicles in Japan
Mar 05, 2026 16:47 JST
DOCOMO's New Haptic-sharing System Enables Fans to Feel Closer to Idols
Mar 05, 2026 16:38 JST
TANAKA Establishes Transfer Technology for its Sintered Gold (Au) Bonding Technology, AuRoFUSE(TM) Preforms
Mar 03, 2026 22:00 JST
Fujitsu and BCN Port Innovation Foundation leverage ocean digital twin technology to drive the regeneration of the Port of Barcelona
Mar 03, 2026 21:00 JST
MHI and SoftBank Corp. Collaborate to Adapt AI-RAN Network Architecture for Edge Data Centers
Mar 02, 2026 19:13 JST
DOCOMO and NEC Launch Japan's First Commercial 5G Core on AWS, Built with World's First AI-automated Network Construction Technology
Mar 02, 2026 16:34 JST
Fujitsu supports sustainable growth for retailers with data and AI through Uvance for Retail
Mar 02, 2026 11:55 JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Mar 02, 2026 09:49 JST
NEC Strengthens Multi-Vendor Optical Network Solutions with New TIP-Certified Phoenix Hardware Lineup
Feb 27, 2026 18:50 JST
NEC Demonstrates Agentic AI-Driven Autonomous Network Operations in Collaboration with AWS
Feb 27, 2026 17:31 JST
Mitsubishi Heavy Industries Compressor Acquires Swiss Rotating Equipment Maintenance Company AST Turbo AG
Feb 27, 2026 17:23 JST
NEC Strengthens Its Edge Portfolio for the 6G Era, Enabling Efficient Edge Deployment and Integration with Cloud Services
Feb 27, 2026 12:24 JST
Fujitsu POS solution enhances customer experience at Hankyu Hanshin Department Stores
Feb 27, 2026 12:03 JST
Mitomo Semicon Engineering to Change Company Name
Feb 26, 2026 22:00 JST
The University of Tokyo, NTT, and NEC demonstrate real-time augmented reality assistance made possible by integrating three newly proposed technologies on a 6G/IOWN platform to realize the widespread use of AI agents supporting safety and security
Feb 26, 2026 19:01 JST
NEC and Nokia to Expand Eletronet's Optical Fiber Network in Brazil by 50%
Feb 26, 2026 18:51 JST
Everest Medicines Shareholders Pass Resolutions Including Commercialization Service Agreement at EGM
Feb 25, 2026 21:59 JST
Toyota Launches New bZ4X Touring BEV Focused on Driving Performance and Spaciousness in Japan
Feb 25, 2026 21:58 JST
More Latest Release >>